Expertise in
1
conditions

Michael A. Fridrik

AKH Linz
Linz, AT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
AKH Linz
Linz, AT 

Overview

Michael Fridrik practices practicing medicine in Linz, Austria.

Mr. Fridrik is highly rated in 1 condition, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Stomach Cancer, and Multiple Myeloma.

He is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

AKH Linz
Linz, 4020, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Thalidomide, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Window of Opportunity Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
A Window of Opportunity Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
Enrollment Status: Terminated
Publish Date: March 03, 2022
Intervention Type: Drug
Study Drugs: Brentuximab, Imatinib
Study Phase: Phase 1/Phase 2
Pilot Study: Biomarker Directed Treatment in Metastatic Colorectal Cancer
Pilot Study: Biomarker Directed Treatment in Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: November 30, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

22 Total Publications

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
Journal: The Lancet. Haematology
Published: June 04, 2018

Frequently Asked Questions about Michael A. Fridrik

Is Michael A. Fridrik a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Michael A. Fridrik is classified as an Advanced expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael A. Fridrik participate in research or clinical trials?

Yes. Michael A. Fridrik has published 22 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Michael A. Fridrik's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fridrik's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile